Login
← Go Back
Evonile Pharma
NOVARTIND · Retail > Trading · Chairman: C Snook · MD: Sanjay Murdeshwar · Listing date: Nov. 9, 2000 · Employees: 539 · Mumbai · http://www.novartis.in
Stock Price vs Company Growth
1d
1.2%
1w
4.5%
1m
6.5%
3m
13.2%
6m
93.1%
1y
119.5%
5y
22.0%
all
21.3%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 1,923 1.2%
1,387
2,588
Company Overview
Sales
371 Cr
Growth: 0.6%
Profit after Tax
97.8 Cr
Growth: 4.9%
Small Cap
4,748 Cr
P/E: 48.5x
Industry P/E: 26.5x
Fundamentals
Sales (Cr) ₹ 371
Growth 0.6%
EBITDA 27.5%
P/S 12.8x
Dividend 2.4%
P/E 48.5x
Book Value ₹ 344
PEG Ratio 86.8x
ROE 11.6%
P/B 5.6x
Shareholding Pattern
Institutions
Promoters
Novartis Ag
70.68 %
Others
Atul Limited
1.52 %
Iepf
0.47 %
Llp, Partnership Firm, Directors' Relative
0.14 %
Increase    Decrease    No change
Company Profile Detailed
As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
Belongs to (9 Indices) view more
Investors (8)
karan.bh...
abdul.ha...
iepf
Followers (1)
varsha96